TY - JOUR
T1 - Benefit finding, posttraumatic growth and health-related quality of life in long-term cancer survivors
T2 - a prospective population-based study
AU - Liu, Zhunzhun
AU - Thong, Melissa S. Y.
AU - Doege, Daniela
AU - Koch-Gallenkamp, Lena
AU - Weisser, Linda
AU - Bertram, Heike
AU - Eberle, Andrea
AU - Holleczek, Bernd
AU - Nennecke, Alice
AU - Waldmann, Annika
AU - Zeissig, Sylke Ruth
AU - Pritzkuleit, Ron
AU - Brenner, Hermann
AU - Arndt, Volker
N1 - Funding Information: This work was supported by two grants from the German Cancer Aid [Nos. 108262, 70112089]. Z.L. was supported by the China Scholarship Council PhD Program (ID number: 201808320419). Publisher Copyright: © 2023 Acta Oncologica Foundation.
PY - 2023
Y1 - 2023
N2 - Background: We explored the relationship between benefit finding (BF)/posttraumatic growth (PTG) at baseline and health-related quality of life (HRQOL) at baseline and follow-up in long-term cancer survivors (LTCS; ≥5-year post-diagnosis). Materials and methods: HRQOL was assessed in LTCS in 2009–2011 (5- to 16-year post-diagnosis, baseline) and re-assessed in 2018/2019 (14- to 24-year post-diagnosis, follow-up). BF and PTG were measured at baseline; mean scores were dichotomized into ‘none-to-low’ (<3) and ‘moderate-to-high’ (> =3). Linear regression models and linear mixed regression models were employed to assess the association of BF/PTG with HRQOL. Results: Of the 6057 baseline participants, 4373 were alive in 2019, of whom 2704 completed the follow-up questionnaire. Cross-sectionally, LTCS with none-to-low BF reported better HRQOL at baseline and at follow-up than LTCS with higher BF. Longitudinally, no difference was found between none-to-low and moderate-to-high BF on the HRQOL change from baseline to follow-up. HRQOL differences between the PTG groups were not statistically significant cross-sectionally and longitudinally, except those participants with moderate-to-high PTG reported higher role functioning and global health status/QOL. Conclusions: Cross-sectionally, BF was significantly negatively related to subscales of HRQOL, while PTG was positively correlated to role functioning and global health status/QOL. The results add further evidence that BF and PTG are two different positive psychological concepts.
AB - Background: We explored the relationship between benefit finding (BF)/posttraumatic growth (PTG) at baseline and health-related quality of life (HRQOL) at baseline and follow-up in long-term cancer survivors (LTCS; ≥5-year post-diagnosis). Materials and methods: HRQOL was assessed in LTCS in 2009–2011 (5- to 16-year post-diagnosis, baseline) and re-assessed in 2018/2019 (14- to 24-year post-diagnosis, follow-up). BF and PTG were measured at baseline; mean scores were dichotomized into ‘none-to-low’ (<3) and ‘moderate-to-high’ (> =3). Linear regression models and linear mixed regression models were employed to assess the association of BF/PTG with HRQOL. Results: Of the 6057 baseline participants, 4373 were alive in 2019, of whom 2704 completed the follow-up questionnaire. Cross-sectionally, LTCS with none-to-low BF reported better HRQOL at baseline and at follow-up than LTCS with higher BF. Longitudinally, no difference was found between none-to-low and moderate-to-high BF on the HRQOL change from baseline to follow-up. HRQOL differences between the PTG groups were not statistically significant cross-sectionally and longitudinally, except those participants with moderate-to-high PTG reported higher role functioning and global health status/QOL. Conclusions: Cross-sectionally, BF was significantly negatively related to subscales of HRQOL, while PTG was positively correlated to role functioning and global health status/QOL. The results add further evidence that BF and PTG are two different positive psychological concepts.
KW - Benefit finding
KW - cancer survivors
KW - health-related quality of life
KW - posttraumatic growth
UR - http://www.scopus.com/inward/record.url?scp=85168284635&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/0284186X.2023.2245560
DO - https://doi.org/10.1080/0284186X.2023.2245560
M3 - Article
C2 - 37594165
SN - 0284-186X
VL - 62
SP - 1124
EP - 1131
JO - Acta Oncologica
JF - Acta Oncologica
IS - 9
ER -